Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain

Published:2021-04-07 Issue:6 Volume:37 Page:1031-1038
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Peres Mario F. P.¹²^ORCID,Vasudeva Raghavendra³,Baygani Simin K.³,Dennehy Ellen B.³⁴,Vincent Maurice³^ORCID,Friedman Deborah I.⁵

Affiliation:

1. Neurology, Hospital Israelita Albert Einstein, São Paulo, Brazil

2. Instituto de Psiquiatria, Hospital das Clínicas da Faculdade de Medicina, São Paulo, Brazil

3. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

4. Psychological Sciences, Purdue University, West Lafayette, IN, USA

5. Neurology and Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA

Funder

Eli Lilly and Company

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1903846

Reference28 articles.

1. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants

2. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators

3. Treatment of Migraine With Rizatriptan: When to Take the Medication

4. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe

5. Early triptan intervention in migraine: an overview

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy;Drug Design, Development and Therapy;2023-07

2. Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial;Cephalalgia;2023-03-23

3. Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks;Cephalalgia;2023-02

4. In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study;The Journal of Headache and Pain;2021-12

5. A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN;The Journal of Headache and Pain;2021-08-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3